DSIP: Benefits, Dosage & FDA Status
Delta Sleep-Inducing Peptide
A nonapeptide originally isolated from rabbit blood after EEG-defined slow-wave sleep induction. Inconsistent human evidence for sleep but explored for stress and analgesia.
FDA Status
Not FDA-approved — research compound
Typical Dose
100–300 mcg before bed (subcutaneous)
Evidence Grade
CPrimarily preclinical or anecdotal
Half-Life
Minutes
Routes of Administration
subcutaneous
First Synthesized
1977
Clinics Indexed
38 providers have offered DSIP in our tracked directory.
Mechanism of Action
Nonapeptide modulating sleep architecture and stress-axis activity; receptor target not fully characterized.
Key Reported Benefits
- ✓Slow-wave-sleep signals (preclinical)
- ✓Stress/cortisol modulation
- ✓Possible analgesic effect
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade C indicates primarily preclinical or anecdotal.
Reported Side Effects
- •Sedation (intended)
- •Vivid dreams
Contraindications
- ⚠Pregnancy
Regulatory & Safety Context
FDA status: Not FDA-approved — research compound
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on DSIP. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
Semax
BA synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.
ARA-290
BAn 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.
Cerebrolysin
BA standardized mixture of low-molecular-weight peptides from porcine brain. Decades of stroke, dementia, and TBI trial data — modest but consistent cognitive recovery effects.
Dihexa
CAn angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.
VIP
BA 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).
Humanin
BA 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.